Ventavis: Uses, Dosage & Side Effects
An inhaled prostacyclin analogue (iloprost) for the treatment of pulmonary arterial hypertension, improving exercise capacity and reducing symptoms in adults with moderate disease
Ventavis (iloprost) is an inhaled prostacyclin analogue prescribed for the treatment of pulmonary arterial hypertension (PAH) in adults. It mimics the natural substance prostacyclin in the blood, widening the blood vessels in the lungs to improve blood flow, reduce the workload on the heart, and enhance exercise capacity. Ventavis is delivered as a fine mist through a specialized nebulizer and is typically used 6 to 9 times per day. Treatment should be initiated and monitored by a physician experienced in managing pulmonary hypertension.
Quick Facts
Key Takeaways
- Ventavis (iloprost) is an inhaled prostacyclin analogue that dilates pulmonary blood vessels and inhibits platelet aggregation, used to treat moderate pulmonary arterial hypertension (PAH) in adults.
- It is administered via specialized nebulizers (Breelib, I-Neb AAD, or Venta-Neb) typically 6 to 9 times daily, with each session lasting approximately 3 to 10 minutes depending on the device.
- Common side effects include flushing, headache, cough, jaw pain, nausea, and an increased risk of bleeding, particularly nosebleeds.
- Ventavis must not be used in patients with active bleeding disorders, recent heart attack or stroke, unstable angina, severe unmonitored heart failure, or pulmonary veno-occlusive disease.
- Treatment should only be initiated by a specialist physician experienced in pulmonary hypertension, and patients require careful monitoring of blood pressure and heart function throughout therapy.
What Is Ventavis and What Is It Used For?
Ventavis contains the active substance iloprost, a synthetic analogue of prostacyclin (also known as prostaglandin I2 or PGI2). Prostacyclin is a naturally occurring substance in the body that plays a critical role in maintaining healthy blood vessel function. It prevents blood vessels from becoming blocked or narrowed, promotes vasodilation, and inhibits platelet aggregation. In patients with pulmonary arterial hypertension, the body's ability to produce sufficient prostacyclin is impaired, leading to progressive narrowing and remodeling of the pulmonary arteries.
Ventavis is specifically approved for the treatment of primary pulmonary hypertension (now more commonly referred to as idiopathic pulmonary arterial hypertension, or IPAH) in adult patients with moderate disease severity, classified as NYHA/WHO functional class III. This means it is intended for patients who experience marked limitation of physical activity, where less-than-ordinary activity causes fatigue, palpitation, dyspnea, or chest pain, but who are comfortable at rest. Pulmonary arterial hypertension is a condition in which the blood pressure in the arteries connecting the heart to the lungs is abnormally elevated, forcing the right side of the heart to work harder to pump blood through the lungs.
How Ventavis Works
When you inhale the Ventavis mist through a nebulizer, the aerosolized iloprost is delivered directly to the lungs, where it acts on the pulmonary arterial vasculature with remarkable selectivity. This targeted delivery means the drug can effectively dilate the blood vessels in the lungs without causing as much systemic vasodilation as intravenous prostacyclin formulations, resulting in fewer body-wide side effects. The improved blood flow through the pulmonary arteries leads to better oxygen supply to the body and a reduction in the workload placed on the right ventricle of the heart.
Beyond its vasodilatory effects, iloprost also possesses antiplatelet properties, preventing the aggregation of blood platelets that can contribute to microthrombus formation within the pulmonary vasculature. Research also suggests that iloprost may have anti-inflammatory and anti-proliferative effects on vascular smooth muscle cells, which could potentially slow the remodeling process that drives the progression of pulmonary arterial hypertension. These combined mechanisms make Ventavis a multifaceted therapeutic agent in the management of PAH.
The landmark AIR study (Aerosolized Iloprost Randomized Study), published in the New England Journal of Medicine, demonstrated that inhaled iloprost significantly improved exercise capacity (as measured by the 6-minute walk distance) and NYHA functional class in patients with pulmonary hypertension compared to placebo. This study formed the basis for the regulatory approval of Ventavis in both the European Union and the United States.
What Should You Know Before Taking Ventavis?
Before beginning treatment with Ventavis, your physician will conduct a thorough evaluation of your medical history, current medications, and overall health status. Several important contraindications and precautions must be considered to ensure that inhaled iloprost therapy is safe and appropriate for you. It is essential that you provide your healthcare team with complete and accurate information about your health to minimize the risk of adverse events.
Contraindications
- You are allergic to iloprost or any other ingredient in the formulation (trometamol, ethanol, sodium chloride, hydrochloric acid, water for injections)
- You have an increased risk of bleeding, such as active gastric or duodenal ulcers, physical trauma, or risk of intracranial hemorrhage
- You have severe coronary artery disease or unstable angina (symptoms may include chest pain)
- You have had a myocardial infarction (heart attack) within the last 6 months
- You have decompensated heart failure that is not under close medical supervision
- You have severe unstable cardiac arrhythmias
- You have a congenital or acquired heart valve defect causing cardiac dysfunction unrelated to pulmonary hypertension
- You have had a stroke or transient ischemic attack (TIA) within the last 3 months
- Your pulmonary hypertension is caused by venous occlusive disease
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before using Ventavis if any of the following apply to you. Special caution is required in several clinical scenarios, and your healthcare team will need to monitor you closely throughout your treatment.
Respiratory effects: Inhalation of Ventavis can cause breathing difficulties, particularly in patients with bronchospasm (sudden constriction of the muscles in the walls of the smaller airways) and wheezing. Inform your doctor if you have a lung infection, severe asthma, or chronic obstructive pulmonary disease (COPD). Your doctor will monitor you carefully and may adjust the treatment approach.
Blood pressure monitoring: Your blood pressure will be checked before starting treatment. If your systolic blood pressure is below 85 mmHg, treatment with Ventavis should not be initiated. Throughout therapy, you should take precautions to minimize the effects of low blood pressure, such as dizziness and fainting. Rise slowly from a sitting or lying position, and avoid excessive physical exertion. If you are prone to fainting, it may help to inhale Ventavis before engaging in physical activity, or to take your first dose while still lying down.
Right heart failure: If you have a weakened heart, particularly right-sided heart failure, and notice worsening symptoms such as swollen feet and ankles, shortness of breath, palpitations, increased nighttime urination, or edema, inform your doctor immediately. Your treatment plan may need to be adjusted.
If you experience difficulty breathing, cough up blood, and/or sweat profusely, these may be signs of fluid accumulation in the lungs (pulmonary edema). Stop using Ventavis immediately and contact your doctor. They will investigate the cause and take appropriate action.
Liver and kidney impairment: If you have liver problems or severe kidney problems requiring dialysis, contact your doctor. You may require a gradual dose escalation or may be prescribed a lower dose of Ventavis compared to other patients. Your physician will carefully titrate your dosing regimen based on how well you tolerate the medication.
Skin Contact and Accidental Ingestion
Do not allow Ventavis solution to come into contact with your skin or eyes. If contact occurs, rinse immediately with copious amounts of water. Do not drink or swallow Ventavis solution. If you accidentally ingest the solution, drink plenty of water and contact your doctor immediately.
Use in Children and Adolescents
The safety and efficacy of Ventavis in children and adolescents under 18 years of age have not been established. Ventavis is not recommended for use in this age group.
Pregnancy and Breastfeeding
Pulmonary hypertension itself carries significant risks during pregnancy and can be life-threatening for both the mother and the unborn child. If you are of childbearing potential, you should use reliable contraception from the start of treatment and throughout the entire course of therapy. If you are pregnant, think you may be pregnant, or are planning to have a baby, inform your doctor immediately. Ventavis should only be used during pregnancy if your physician determines that the potential benefits outweigh the risks to you and the fetus.
It is unknown whether iloprost or its metabolites are excreted in human breast milk. A potential risk to the nursing infant cannot be excluded, and breastfeeding should therefore be avoided during treatment with Ventavis. Additionally, newborns, infants, and pregnant women should not be in the room while you are inhaling Ventavis, as they could inadvertently be exposed to the aerosolized medication.
Driving and Operating Machinery
Ventavis lowers blood pressure and may cause dizziness or light-headedness in some individuals. Do not drive a vehicle or operate tools or machinery if you experience these effects. You should assess your individual response to the medication before engaging in activities that require alertness and coordination.
Ventavis 10 micrograms/ml contains 0.81 mg of alcohol (ethanol) per ml, corresponding to 0.081% w/v. The amount of alcohol in 1 ml of this medicine is equivalent to less than 1 ml of beer or wine. The small quantity of alcohol in this medicine will not produce any noticeable effects.
How Does Ventavis Interact with Other Drugs?
Drug interactions are an important consideration when using Ventavis, as several commonly prescribed medications can enhance or modify its effects. Because iloprost has both vasodilatory and antiplatelet properties, combining it with other drugs that lower blood pressure or affect blood clotting can increase the risk of serious adverse events. You should inform your doctor about all prescription medications, over-the-counter drugs, and supplements you are currently taking or have recently used.
Major Interactions
The following categories of medications warrant particular attention when used concurrently with Ventavis, as they may significantly amplify its effects on blood pressure and hemostasis:
| Drug Class | Examples | Interaction Effect | Clinical Action |
|---|---|---|---|
| Antihypertensives | Beta-blockers, ACE inhibitors, calcium channel blockers | Enhanced blood pressure lowering; risk of significant hypotension | Dose adjustment may be required; monitor blood pressure closely |
| Nitrate vasodilators | Nitroglycerin, isosorbide mononitrate | Additive vasodilation; risk of severe hypotension | Use with caution; close hemodynamic monitoring |
| Anticoagulants | Warfarin, heparin, phenprocoumone | Increased bleeding risk due to additive antiplatelet effects | Close monitoring of coagulation parameters; watch for signs of bleeding |
| Antiplatelet agents | Aspirin (ASA), clopidogrel, ticlopidine | Increased bleeding risk; enhanced inhibition of platelet aggregation | Careful monitoring; report unusual bruising or bleeding immediately |
| Glycoprotein IIb/IIIa inhibitors | Abciximab, eptifibatide, tirofiban | Significantly increased bleeding risk | Close monitoring required; concurrent use should be carefully evaluated |
Other Interactions
Several additional drug classes can interact with Ventavis and require awareness:
- NSAIDs (non-steroidal anti-inflammatory drugs): May increase bleeding risk through combined effects on platelet function and gastric mucosa
- Non-selective phosphodiesterase inhibitors (e.g., pentoxifylline): Can enhance the vasodilatory and antiplatelet effects of iloprost
- Selective PDE-3 inhibitors (e.g., cilostazol, anagrelid): May potentiate antiplatelet effects
- Defibrotide: Can increase bleeding risk when used concurrently with prostacyclin analogues
Food and drink are not expected to affect Ventavis. However, you should avoid eating or drinking during the inhalation sessions to ensure optimal drug delivery and to prevent aspiration.
What Is the Correct Dosage of Ventavis?
Treatment with Ventavis should only be initiated by a physician experienced in managing pulmonary hypertension. The dosage is individualized based on your clinical condition, tolerance, and response to therapy. You should always use this medicine exactly as your doctor has instructed and should never change the recommended dose without first consulting your physician.
Adults
The standard dosing regimen for Ventavis involves 6 to 9 inhalation sessions spread throughout the day. Treatment typically begins with a lower dose of 2.5 micrograms of iloprost delivered through the mouthpiece, which is then increased to 5 micrograms per session if the initial dose is well tolerated. If the 5-microgram dose is not tolerated, the dose should be reduced back to 2.5 micrograms. The specific dosing protocol depends on which nebulizer system is used.
| Nebulizer | Ampoule | Dose at Mouthpiece | Inhalation Time | Sessions per Day |
|---|---|---|---|---|
| Breelib | 1 ml (white-yellow rings) | 2.5 micrograms | ~3 minutes | 6-9 |
| I-Neb AAD | 1 ml (white-yellow rings) | 2.5 or 5 micrograms | ~3-7 minutes | 6-9 |
| Venta-Neb | 2 ml (white-pink rings) | 2.5 or 5 micrograms | ~4-8 minutes | 6-9 |
When using the Breelib nebulizer, treatment starts with Ventavis 10 micrograms/ml (1 ml ampoule with white and yellow rings). If this dose is well tolerated, the next inhalation may use Ventavis 20 micrograms/ml (ampoule with yellow and red rings), which should then be continued. If the higher concentration is not tolerated, your doctor may decide to continue with the 10 micrograms/ml formulation.
The I-Neb AAD system uses a vibrating mesh technology and provides two dose options controlled by color-coded medicine chambers and control discs. The red medicine chamber and red control disc deliver 2.5 micrograms, while the purple medicine chamber and purple control disc deliver 5 micrograms. Always verify that the chamber and disc colors match.
The Venta-Neb system offers two programs: P1 (program 1) delivers 5 micrograms through 25 inhalation cycles, and P2 (program 2) delivers 2.5 micrograms through 10 inhalation cycles. Your doctor will configure the appropriate program. The green baffle should be used for optimal droplet size.
Renal and Hepatic Impairment
Renal Impairment
No dose adjustment is necessary for patients with mild to moderate kidney problems (creatinine clearance > 30 ml/min). For patients with severe kidney problems requiring dialysis, the physician will initiate Ventavis gradually, starting at 2.5 micrograms with dosing intervals of 3-4 hours (maximum 6 administrations per day), then carefully shortening the intervals based on tolerability.
Hepatic Impairment
For patients with liver problems, the physician will initiate Ventavis gradually, starting at 2.5 micrograms with dosing intervals of 3-4 hours (maximum 6 administrations per day). The intervals may then be carefully shortened depending on tolerability. If the physician decides to increase the dose to 5 micrograms, dosing intervals of 3-4 hours should again be used initially.
Children
Ventavis is not recommended for use in children and adolescents under 18 years of age due to a lack of safety and efficacy data in this population. Decisions regarding pediatric use in exceptional circumstances should be made by specialized pulmonary hypertension centers on a case-by-case basis.
How to Inhale Ventavis
Use a new Ventavis ampoule for each inhalation session. Just before you begin, break the glass ampoule and pour the solution into the nebulizer medicine chamber, following the manufacturer's instructions for your specific device. Always use a mouthpiece (not a face mask) to prevent Ventavis from contacting your skin. After each session, discard any solution remaining in the nebulizer. Ensure that the room is well-ventilated during and after inhalation, as other people could inadvertently inhale the aerosolized medication.
Do not switch between nebulizer devices without consulting your physician. Different nebulizers produce aerosols with slightly different physical characteristics and may deliver the solution at different rates. Your doctor needs to supervise any change in device to ensure safe and effective dosing.
Missed Dose
If you miss an inhalation session, do not take a double dose to make up for it. Simply continue with your next scheduled inhalation and consult your doctor if you are unsure about what to do.
Overdose
Using too much Ventavis may cause dizziness, headache, flushing, nausea, jaw pain, or back pain. It may also result in low or elevated blood pressure, bradycardia (slow heart rate), tachycardia (fast heart rate), vomiting, diarrhea, or limb pain. If you experience any of these symptoms from using too much Ventavis, stop the inhalation immediately and contact your doctor. There is no specific antidote; your doctor will monitor you and treat the symptoms as they arise.
What Are the Side Effects of Ventavis?
Like all medicines, Ventavis can cause side effects, although not everyone experiences them. The side effects are largely a consequence of its pharmacological action as a prostacyclin analogue, resulting in vasodilation and antiplatelet effects. Understanding the frequency and nature of these side effects will help you recognize when to seek medical attention and when symptoms can be managed with routine care.
- Severe bleeding, including coughing up blood or signs of intracranial hemorrhage
- Fainting (syncope) or severe dizziness
- Significant drop in blood pressure
- Severe difficulty breathing or sudden wheezing (bronchospasm)
- Signs of pulmonary edema: difficulty breathing with coughing up blood and excessive sweating
Very Common
May affect more than 1 in 10 people
- Vasodilation (flushing, facial redness)
- Chest discomfort or chest pain
- Cough
- Headache
- Nausea
- Jaw pain or jaw muscle spasm (trismus)
- Peripheral edema (swelling of arms, hands, legs, feet)
- Bleeding events, especially nosebleeds (epistaxis) and coughing up blood (hemoptysis)
Common
May affect up to 1 in 10 people
- Syncope (fainting)
- Hypotension (low blood pressure)
- Dyspnea (difficulty breathing)
- Dizziness
- Vomiting
- Diarrhea
- Pharyngeal irritation (pain when swallowing)
- Throat irritation
- Mouth and tongue irritation or pain
- Rash
- Tachycardia (rapid heart rate)
- Palpitations
Not Known
Frequency cannot be estimated from available data
- Thrombocytopenia (decrease in blood platelet count)
- Hypersensitivity (allergic) reactions
- Dysgeusia (taste disturbance)
- Bronchospasm (sudden airway constriction) and wheezing
Bleeding Risk
Bleeding events, particularly nosebleeds and hemoptysis (coughing up blood), are among the most frequently reported side effects of Ventavis. The risk of bleeding is particularly elevated in patients who are concurrently taking anticoagulants (blood thinners such as warfarin or heparin) or antiplatelet agents (such as aspirin or clopidogrel). Very rare, fatal cases of intracranial (cerebral) hemorrhage have been reported in post-marketing surveillance. If you notice any unusual or excessive bleeding, contact your healthcare provider immediately.
Understanding Peripheral Edema
Swelling of the ankles and legs (peripheral edema) is a very common symptom of pulmonary arterial hypertension itself, resulting from right heart strain and fluid retention. This symptom may also occur during Ventavis therapy. It is important to distinguish between edema that is part of your underlying condition and edema that may represent worsening heart function. Report any new or worsening swelling to your physician so that appropriate adjustments can be made.
Reporting Side Effects
Reporting suspected side effects after a medicine has been authorized is important, as it allows ongoing monitoring of the benefit-risk balance of the medication. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority (e.g., FDA MedWatch in the United States, EMA EudraVigilance in the European Union, or the MHRA Yellow Card Scheme in the United Kingdom).
How Should You Store Ventavis?
Proper storage of Ventavis is essential to maintain the medication's efficacy and safety. The solution should be kept out of the sight and reach of children at all times. Use the medication before the expiration date indicated on both the outer packaging and the individual ampoule. No special storage temperature or humidity conditions are required for the sealed ampoules.
After each inhalation session, any remaining Ventavis solution in the nebulizer must be discarded. The solution is intended for single use only, and reusing leftover solution may compromise sterility and drug integrity. Do not dispose of medicines in household waste or by pouring them down the drain. Ask your pharmacist about the proper disposal of medications that are no longer needed, as these measures help protect the environment.
What Does Ventavis Contain?
Active Ingredient
Each milliliter of Ventavis solution contains 10 micrograms of iloprost (as iloprost trometamol). The 1 ml ampoules therefore contain 10 micrograms of iloprost, while the 2 ml ampoules contain 20 micrograms of iloprost. The iloprost trometamol salt form was selected for its optimal stability in aqueous solution and suitability for nebulization.
Inactive Ingredients
The other components of Ventavis are trometamol (a buffer to maintain pH stability), ethanol (in very small quantities), sodium chloride (to ensure isotonicity), hydrochloric acid (for pH adjustment), and water for injections. These excipients serve to create a stable, isotonic solution that is suitable for aerosolization through nebulizer devices.
Appearance and Packaging
Ventavis is a clear, colorless solution for nebulizer inhalation, supplied in colorless glass ampoules. The ampoules are identified by colored rings:
- 1 ml ampoules (white-yellow rings): For use with Breelib or I-Neb AAD nebulizers. Available in packs of 30 or 42 ampoules, and multipack sizes of 168 (4×42) ampoules.
- 2 ml ampoules (white-pink rings): For use with the Venta-Neb nebulizer. Available in packs of 30, 90, 100, or 300 ampoules, and multipacks of 90 (3×30) or 300 (10×30) ampoules.
Not all pack sizes may be marketed in all countries. Ventavis is manufactured by Berlimed S.A. in Alcala de Henares, Madrid, Spain, and is marketed by Bayer AG, Leverkusen, Germany.
Frequently Asked Questions About Ventavis
Ventavis (inhaled iloprost) is a prostacyclin analogue delivered directly to the lungs via a nebulizer, which provides targeted vasodilation of the pulmonary vasculature with fewer systemic side effects compared to intravenous prostacyclin formulations (such as epoprostenol). Other PAH treatments include endothelin receptor antagonists (e.g., bosentan, ambrisentan), phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil), and soluble guanylate cyclase stimulators (e.g., riociguat). Your pulmonary hypertension specialist will determine the most appropriate treatment or combination therapy based on your disease severity and individual response.
The duration of each inhalation session depends on which nebulizer device you use. The Breelib nebulizer is the fastest, typically completing an inhalation in approximately 3 minutes. The I-Neb AAD device takes approximately 3 to 7 minutes depending on the dose (2.5 or 5 micrograms). The Venta-Neb system takes approximately 4 to 8 minutes. Your physician will help you select the most suitable device based on your lifestyle, treatment needs, and ability to perform the inhalation correctly.
No, you should never stop Ventavis without first discussing it with your physician. Pulmonary arterial hypertension is a chronic condition, and Ventavis is typically used as a long-term treatment. Sudden discontinuation could lead to a rebound worsening of your pulmonary hypertension symptoms. If you wish to stop treatment or are considering any changes, always consult your doctor first so that a safe plan can be developed.
Patients with pulmonary arterial hypertension should consult their physician before air travel, as the reduced cabin pressure at altitude can worsen hypoxia. While taking Ventavis, you will need to consider how to continue your inhalation schedule during travel. Discuss travel plans with your healthcare team, who can advise on supplemental oxygen requirements and practical arrangements for using your nebulizer during the journey.
Room ventilation is important because aerosolized iloprost can disperse into the surrounding air during and after your inhalation session. Other people in the room, particularly newborns, infants, and pregnant women, could inadvertently be exposed to the drug through ambient air. Proper ventilation minimizes this unintentional exposure and ensures the safety of those around you. Open a window or ensure adequate airflow during and after each inhalation session.
If Ventavis solution comes into contact with your skin or eyes, rinse the affected area immediately with copious amounts of clean water. While brief skin contact is unlikely to cause significant harm, prolonged exposure could lead to local vasodilation effects. If irritation persists or if you experience any eye discomfort, contact your doctor or seek medical advice.
References
- European Medicines Agency (EMA). Ventavis (iloprost) - Summary of Product Characteristics. Last updated 2024. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Ventavis (iloprost) Inhalation Solution - Prescribing Information. Revised 2024.
- Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-329. doi:10.1056/NEJMoa020204
- Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237
- Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67-119.
- World Health Organization (WHO). Model List of Essential Medicines - 23rd List. Geneva: WHO; 2023.
- McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. J Am Coll Cardiol. 2009;53(17):1573-1619.
- British National Formulary (BNF). Iloprost. Available at: bnf.nice.org.uk
Editorial Team
This article has been written and reviewed by licensed medical professionals with expertise in pulmonary medicine, cardiology, and clinical pharmacology.
Medical Author
iMedic Medical Editorial Team - Specialists in Pulmonary Medicine and Clinical Pharmacology
Medical Reviewer
iMedic Medical Review Board - Independent panel following ESC/ERS, WHO, and GRADE guidelines
Evidence Framework
GRADE (Grading of Recommendations Assessment, Development and Evaluation) - Level 1A Evidence
Editorial Standards
Peer-reviewed, no commercial funding, no pharmaceutical sponsorship